Европейский рынок реагентов и оборудования для трансфекции – тенденции отрасли и прогноз до 2030 года

Анализ и аналитика европейского рынка реагентов и оборудования для трансфекции

Трансфекция включает введение нуклеиновой кислоты в эукариотические клетки вирусными и невирусными методами. Метод трансфекции может преодолеть проблему переноса отрицательно заряженной мембраны. Химические вещества , такие как фосфат кальция и диэтиламиноэтил (DEAE)-декстран или реагент на основе катионного липида, реагируют с внешней оболочкой ДНК. Он нейтрализует общий отрицательный заряд, придает молекуле положительное количество и, следовательно, позволяет доставлять ДНК. Физические методы, такие как электропорация, создают мельчайшие поры в клеточной мембране путем приложения электрического напряжения, что позволяет ДНК проникать непосредственно в цитоплазму. DEAE-декстран используется для временной трансфекции; однако липофекция может обеспечить стабильную трансфекцию и, следовательно, может использоваться для долгосрочной экспрессии белка. Трансфекция, опосредованная фосфатом кальция, также может использоваться для стабильной трансфекции. Метод вирусной трансфекции достигает высокой эффективности и используется на нескольких этапах разработки фармацевтической продукции.

Метод трансфекции используется в нескольких приложениях, включая сельское хозяйство, для защиты урожая и повышения урожайности, для производства синтетических биологических продуктов для улучшения вкусов и ароматов, а также для улучшения одноклеточного белка и т. д. Спрос на трансфекцию увеличился как в развитых, так и в развивающихся странах, и причиной этого является рост числа хронических заболеваний. Рынок трансфекции растет из-за растущего спроса на химерные гены и использования биофармацевтических препаратов в производстве белков. Рынок будет расти в прогнозируемый период из-за исследования развивающихся рынков, стратегических инициатив участников рынка и увеличения государственной поддержки.

Ожидается, что высокая стоимость инструментов, избирательная эффективность реагентов для трансфекции и повреждение клеток, вызванное методами трансфекции, будут сдерживать рост европейского рынка реагентов и оборудования для трансфекции.

Рынок растет благодаря ряду стратегических инициатив, принятых участниками рынка, включающих приобретения, сотрудничество и партнерство.

По данным исследования рынка Data Bridge, ожидается, что к 2030 году объем европейского рынка реагентов и оборудования для трансфекции достигнет 513 494,89 тыс. долларов США, а среднегодовой темп роста в прогнозируемый период составит 8,6%.

Определение рынка

The transfection method is used to introduce RNA, DNA or protein products in cells to alter the phenotype and genotype of the organism. The transfection method involves the new gene transfer or transferring a gene construct such as Clustered regularly interspaced short palindromic repeats (CRISPR) for genome editing purposes. Transfection has wide applications in the field of immunotherapy, gene therapy, and cell therapy, among others. Transfection involves both non-viral and viral-mediated transfection. The chemical and physical methods can achieve non–viral transfection. The most common chemical method used for transfection is calcium phosphate transfection, and liposome transfection, among others. Viral transfection yields high transfection efficiencies, and various types of physical methods employed for transfection include microinjection, biolistic particle delivery, and electroporation, among which electroporation provides high transfection efficiency. Transfection is of two types either it can be transient or stable transfection. For short-term gene expression studies such as gene knock-out studies, small-scale production transient transfection method is preferred; however, long-term research studies and large-scale protein production stable transfection methods are widely adopted.

Europe Transfection Reagent and Equipment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• RISE IN THE PREVALENCE OF CHRONIC DISEASES

The prevalence of chronic diseases is increasing worldwide, leading to the demand for effective and accurate treatment. Transfection is used to deliver targeted modified genes to treat several genetic diseases. The transfection method is also used for the delivery of the CRISPR gene, which can enhance adaptive immunity and prevent an individual from different diseases.

The increasing cases of chronic diseases such as COVID-19 and other infectious diseases have led to the discovery of effective gene therapy products which can replace the defective gene with the correct gene. The transfection method is widely used for gene therapy, among others. As the demand for effective and accurate treatment is increasing worldwide, the demand for gene therapy and transfection method is also increasing. Moreover, several undergoing researches proving gene therapy to have the potential for chronic disease treatment are also increasing its demand among physicians and patients. This thus signifies that the rise in chronic disease prevalence is acting as a driver for the Europe transfection Reagent and equipment market growth.

• DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS

Synthetic biology is a new era of biology that incorporates the engineering principle into biology. Synthetic biology involves the chemical synthesis of DNA by combining the knowledge of genomics to reassemble the DNA genomes. The synthetic biology that sequences into the new genes involves genetic engineering, which incorporates the transfection method, among others. As the demand for synthetic biology products is increasing worldwide, the use of transfection products is also increasing.

The demand for synthetic biology products is increasing due to the increasing demand for effective and innovative products. The manufacturing of synthetic products enhances the demand for transfection products, as gene transfer can be accompanied by the transfection method, among others. Thus, this signifies that synthetic product development drives the Europe transfection Reagent and equipment market growth.

Restraint

• CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE

Some transfection methods have been reported to cause cell damage, reducing the reproducibility of the overall method. Among the several kinds of transfection procedures, electroporation has been reported to cause maximum cell damage as per the increase in voltage. This cell damage lowers the efficiency rate and impacts the ongoing project.

One of the most common side effects of the transfection procedure is cell damage which lowers the cells metabolic events and leads to cell death. This damaged cell can enhance the media toxicity and hence produces inappropriate results. Thus, this suggests that cell damage induced by the transfection procedure acts as a restraint for the Europe transfection Reagent and equipment market growth.

Opportunity

• EXPLORATION OF EMERGING MARKET

The transfection products have been shown as promising tools for the genetic engineering and proteomic industry. The top market for transfection products is in Europe and North America. By looking at the positive outcomes of these products, many market players are penetrating their roots in growing economies involving China and India, among others. The emerging market allows these market players to combat the loss that arises from the well-established market.

As emerging markets allow the market players to overcome the economic downturn specified to particular established markets, investment and exploration of emerging markets allow the market players to engage in the development and manufacturing of transfection products to attain lucrative growth. Thus, this signifies that exploring emerging markets is an opportunity to grow the Europe transfection Reagent and equipment market.

Challenge

• LONG APPROVAL PROCEDURE

The long approval procedure for transfection Reagent and instruments is a hindering agent for the growth of the transfection market. Transfection products are subjected to extensive regulations and have to monitor every time. The transfection products are widely used for the insertion of desired gene molecules in a particular cell line to obtain proteins and other biological compounds. This process is thus investigated and approved by the long and strict regulatory procedures. The long process required to get a positive result from every conducted clinical trial led to more time consumption and the investment of lots of money by market players.

The transfection Reagent are mostly subjected to 21CFR parts 210 and 211 U.S. FDA guidelines, according to which the manufacturers had to assure that the reagent manufactured meets the safety, packaging and processing characteristics proposed by the regulatory agencies. The owner or manufacturer has to submit licenses under section 351 of the PHS (Public Health Services) Act, which is quite a tedious procedure. Thus, this signifies that long approval procedures challenge the Europe transfection Reagent and equipment market growth.

Recent Developments

• In August 2021, Mirus Bio expanded the TransIT VirusGen platform for Good Manufacturing Practice (GMP) viral vector production to support cell and gene therapy development, process operations, and commercial production. The extension, referred to as TransIT VirusGen GMP Transfection Reagent, is designed to improve the packaging and delivery of vector DNA to suspension and adherent HEK 293 cell types to improve the production of recombinant adeno-associated viruses and lentiviral vectors.
• In April 2021, BOC Sciences announced the launch of two in vivo RNA transfection kits, namely siRNA in vivo transfection kits and mRNA in vivo transfection kits, suitable for in vivo transfection of siRNA and mRNA, respectively.

Europe Transfection Reagent and Equipment Market Scope

Europe transfection Reagent and equipment market is segmented into nine notable segments such as products, stage, methods, type, types of molecule, application, end user, organism, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

PRODUCTS

• INSTRUMENTS
• REAGENT & KITS

On the basis of products, the Europe transfection reagent and equipment market is segmented into instruments and reagent & kits.

STAGE

• RESEARCH
• PRECLINICAL
• CLINICAL PHASES
• COMMERCIAL

On the basis of stage, the Europe transfection reagent and equipment market is segmented into research, preclinical, clinical phases and commercial.

TYPE

• TRANSIENT TRANSFECTION REAGENT AND EQUIPMENT
• STABLE TRANSFECTION REAGENT AND EQUIPMENT

On the basis of type, the Europe transfection reagent and equipment market is segmented into transient transfection reagent and equipment and stable transfection reagent and equipment.

METHODS

• NON-VIRAL METHODS
• VIRAL METHODS

On the basis of methods, the Europe transfection reagent and equipment market is segmented into non-viral methods and viral methods.

TYPES OF MOLECULE

• PLASMID DNA
• DNA OLIGONUCLEOTIDES
• SMALL INTERFERING RNA (SIRNA)
• PROTEINS
• RIBONUCLEOPROTEIN COMPLEXES (RNPS)
• OTHERS

On the basis of types of molecule, the Europe transfection reagent and equipment market is segmented into plasmid DNA, DNA oligonucleotides, small interfering RNA (siRNA), proteins, ribonucleoprotein complexes (RNPs) and others.

ORGANISM

• BACTERIA
• MAMMALIAN CELLS
• FUNGI
• PLANTS
• VIRUS

On the basis of organism, the Europe transfection reagent and equipment market is segmented into bacteria, mammalian cells, fungi, plants and virus.

APPLICATION

• BY TYPE
  • IN VITRO APPLICATION
  • IN VIVO APPLICATION
  • BIOPRODUCTION
  • OTHERS
• BY INDUSTRY
  • AGRICULTURE
  • SYNTHETIC BIOLOGY
  • OTHERS

On the basis of application, the Europe transfection reagent and equipment market is segmented by type into in vitro application, in vivo application, bioproduction, others and by industry into agriculture, synthetic biology, others.

END USER

• BIOPHARMA
• CROS
• CMOS/CDMOS
• ACADEMIA
• HOSPITALS
• CLINICAL LABS
• OTHERS

On the basis of end user, the Europe transfection reagent and equipment market is segmented into biopharma, CROs, CMOs/ CDMOs, academia, hospitals, clinical labs and others.

DISTRIBUTION CHANNEL

• DIRECT TENDER
• RETAIL SALES
• OTHERS

On the basis of distribution channel, the Europe transfection Reagent and equipment market is segmented into direct tender, retail sales and others.

Europe Transfection Reagent and Equipment Market Regional Analysis/Insights

The Europe transfection reagent and equipment market is categorized into many notable segments such as geography, products, stages, methods, type, types of molecule, application, end user, organism, and distribution channel.

The countries covered in this market report are Germany, France, Italy, U.K., Spain, Switzerland, Russia, Netherlands, Belgium, Turkey, and Rest of Europe.

In 2023, Germany dominates Europe region due to the increasing demand from emerging markets and expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Transfection Reagent and Equipment Market Share Analysis

Конкурентная среда европейского рынка реагентов и оборудования для трансфекции содержит сведения по конкурентам. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в НИОКР, новые рыночные инициативы, производственные площадки и объекты, сильные и слабые стороны компании, запуск продукта, одобрение продукта, широта и диапазон продукта, доминирование приложений, кривая жизненного цикла типа продукта. Приведенные выше данные относятся только к фокусу компании на европейском рынке реагентов и оборудования для трансфекции.

Некоторые из основных игроков, работающих на этом рынке, включают Mirus Bio LLC., Promega Corporation, Polyplus Transfection, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Altogen Biosystems, SBS Genetech, FUJIFILM Irvine Scientific (дочерняя компания FUJIFILM Holdings Corporation), Avanti Polar Lipids (дочерняя компания Croda International Plc), PerkinElmer chemagen Technologie GmbH (дочерняя компания PerkinElmer Inc.), Cytiva, Geno Technology Inc., USA, R&D Systems, Inc., Takara Bio Inc., Thermofisher Scientific Inc., Roche Molecular Systems, Inc. (дочерняя компания F. Hoffmann-La Roche Ltd), QIAGEN, OriGene Technologies, Inc., Applied Biological Materials Inc. (abm), Beckman Coulter, Inc. (дочерняя компания Дочерняя компания Danaher), Amyris, Codexis, Autolus, SignaGen Laboratories, Impossible Foods Inc., Genlantis Inc., Ginkgo Bioworks, Verve Therapeutics, Inc., Conagen, Inc., Poseida Therapeutics, Inc. и Twist Bioscience и другие.

SKU-1933